TY - JOUR
T1 - Progress Toward Long-Term Survivors of Glioblastoma
AU - Cantrell, J. Nathan
AU - Waddle, Mark R.
AU - Rotman, Maarten
AU - Peterson, Jennifer L.
AU - Ruiz-Garcia, Henry
AU - Heckman, Michael G.
AU - Quiñones-Hinojosa, Alfredo
AU - Rosenfeld, Steven S.
AU - Brown, Paul D.
AU - Trifiletti, Daniel M.
N1 - Publisher Copyright:
© 2019 Mayo Foundation for Medical Education and Research
PY - 2019/7
Y1 - 2019/7
N2 - Objective: To identify the frequency and characteristics of long-term survivors of glioblastoma. Patients and Methods: Using all cases of glioblastoma with histopathological confirmation in the National Cancer Database from January 1, 2004, through December 31, 2009, clinical, institutional, and treatment-related factors were evaluated with multivariable logistic regression models so as to elucidate factors independently associated with higher than 5-year overall survival after diagnosis. Results: A total of 48,652 patients met the inclusion criteria, with 2249 (4.6%) achieving 5-year survival. Factors associated with odds of improved 5-year overall survival in multivariable analysis were younger age, female sex, less medical comorbidities, nonwhite race, highest median income quartile, left-sided tumors and tumors outside the brainstem, and treatment with radiotherapy (P<.05 for all). The percentage of patients surviving 5 years remained relatively unchanged over the 6-year study period (P=.97). Conclusion: Despite improvements in median and short-term overall survival shown in recent large clinical trials for glioblastoma, the percentage of patients with glioblastoma achieving 5-year overall survival remains low. This observation calls for the development of practice-redefining therapies and justifies the increased application of radical novel and experimental treatment paradigms for all patients with glioblastoma.
AB - Objective: To identify the frequency and characteristics of long-term survivors of glioblastoma. Patients and Methods: Using all cases of glioblastoma with histopathological confirmation in the National Cancer Database from January 1, 2004, through December 31, 2009, clinical, institutional, and treatment-related factors were evaluated with multivariable logistic regression models so as to elucidate factors independently associated with higher than 5-year overall survival after diagnosis. Results: A total of 48,652 patients met the inclusion criteria, with 2249 (4.6%) achieving 5-year survival. Factors associated with odds of improved 5-year overall survival in multivariable analysis were younger age, female sex, less medical comorbidities, nonwhite race, highest median income quartile, left-sided tumors and tumors outside the brainstem, and treatment with radiotherapy (P<.05 for all). The percentage of patients surviving 5 years remained relatively unchanged over the 6-year study period (P=.97). Conclusion: Despite improvements in median and short-term overall survival shown in recent large clinical trials for glioblastoma, the percentage of patients with glioblastoma achieving 5-year overall survival remains low. This observation calls for the development of practice-redefining therapies and justifies the increased application of radical novel and experimental treatment paradigms for all patients with glioblastoma.
UR - http://www.scopus.com/inward/record.url?scp=85067548238&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85067548238&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2018.11.031
DO - 10.1016/j.mayocp.2018.11.031
M3 - Article
C2 - 31230743
AN - SCOPUS:85067548238
SN - 0025-6196
VL - 94
SP - 1278
EP - 1286
JO - Mayo Clinic proceedings
JF - Mayo Clinic proceedings
IS - 7
ER -